Vasculitis & polymyalgia rheumatica
Glucocorticoid treatment and clinical outcomes in patients with polymyalgia rheumatica: A cohort study using routinely collected health data
Authors' conclusion
The incidence of GC-related AEs was associated with the GC dose in PMR patients.
Study context
- Population
- Newly diagnosed PMR patients aged ≥50 years with CRP ≥10 mg/L and/or ESR >30 mm/h and initial glucocorticoid (GC) ≥5 mg/day, Japanese EMR database (mean age 77.3 years)analysed
- Participants
- 373 participants
- Outcome
- GC dose, inflammatory parameters (CRP, ESR) and GC-related AEs
- Follow-up
- Week 52
Methodological detailsJapanese electronic medical records database, routinely collected health data
- Japanese electronic medical records database
- Routinely collected health data
Main finding
As reported in the abstract
Real-world GC therapy
- Median initial GC dose (mg/day)
- 15.0
- Median GC dose by week 52 (mg/day)
- 3.5
- Median cumulative GC dose at week 52 (mg)
- 2455.0
- Median CRP on day 0 (mg/L)
- 64.3
- CRP during weeks 4-52 (mg/L)
- 1.4-3.2
- CRP >3.0 mg/L at week 52
- 39.0%
Observational data: associations, not effects.
Safety
Cumulative incidence of GC-related adverse events (AEs) · week 52
- Osteoporosis
- 49.0%
- Diabetes
- 30.2%
- Hypertension
- 14.9%
- Peptic ulcer
- 12.2%
- Dyslipidaemia
- 11.3%
- Glaucoma
- 2.9%
- Serious infection
- 4.3%
- Incidence of osteoporosis and diabetes increased with GC dose
Original publication
Glucocorticoid treatment and clinical outcomes in patients with polymyalgia rheumatica: A cohort study using routinely collected health data. Joint Bone Spine. Published 22 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →